Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab

BACKGROUND: Clinical observations suggested that a non negligible proportion of patients, ranging from 40% to 70%, does not seem to benefit from the use of anti-EGFR targeted antibodies even in the absence of a mutation of the K- RAS gene. The EGFR pathway activation via the Ras-Raf-MAP-kinase and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Scartozzi, Mario, Giampieri, Riccardo, Maccaroni, Elena, Mandolesi, Alessandra, Biagetti, Simona, Alfonsi, Simona, Giustini, Lucio, Loretelli, Cristian, Faloppi, Luca, Bittoni, Alessandro, Bianconi, Maristella, Del Prete, Michela, Bearzi, Italo, Cascinu, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433313/
https://www.ncbi.nlm.nih.gov/pubmed/22490361
http://dx.doi.org/10.1186/1479-5876-10-71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433313/
https://www.ncbi.nlm.nih.gov/pubmed/22490361
http://dx.doi.org/10.1186/1479-5876-10-71

Ejemplares similares